不同富裕程度的患者接受的小儿骨肉瘤治疗是否不同?单中心经验
该回顾性治疗研究纳入2006年至2022年美国中大西洋地区一家大型小儿三级癌症中心的113例18岁以下骨肉瘤患儿,按儿童机会指数三分位分组,比较就诊时间、化疗与手术时机及类型、疾病严重程度和生存。结果显示各机会指数三分位组间在上述指标上均无显著差异,作者认为就医可及性和区域保险政策可能有助于缩小差异,未来需多中心研究。
要点
- 儿童机会指数最低、中间、最高三分位组从症状出现到首次门诊就诊时间无显著差异(p=0.3)。
- 三组在首次门诊到首次化疗时间、手术切除时间及保肢与截肢比例上均无显著差异。
- 三组5年无病生存、总生存及排除转移患者后的生存均无显著差异。
核心结论
- 在该单中心回顾性研究的113例骨肉瘤患儿中,未发现患者全国社会经济机会与其就诊时间、化疗治疗、手术切除时间及类型、无病生存和总生存之间存在关联。
- 作者认为就医距离近、公共交通便利和区域保险政策可能有助于缩小差异,未来需多中心研究进一步探讨区域差异及上述因素在骨肉瘤治疗中的作用。
研究设计与样本
- 回顾性治疗研究,数据来自美国中大西洋地区一家大型小儿三级癌症中心2006年至2022年的机构记录。
- 排除寻求第二意见或该机构非主要骨科诊疗点的患者45例(20%,45/223),以及电子病历不完整43例(24%,43/178)、居住在国外9例(5%,9/178)、复发后就诊8例(4%,8/178)、在该机构随访不足2年5例(3%,5/178)的患者。
- 最终纳入113例18岁以下骨肉瘤患儿,按儿童机会指数全国评分三分位分组:最低三分位<34分,中间三分位34至66分,最高三分位>66分。
- 采用卡方检验和Fisher精确检验比较分类变量,Mann-Whitney U检验比较连续数据,Kaplan-Meier生存分析分层评估5年转移性疾病发展和总生存,log-rank检验评估统计学显著性。
主要发现
- 从症状出现到首次门诊就诊时间:最低三分位均值±标准差77±67天(95%CI 60至94),中间三分位69±94天(95%CI 50至89),最高三分位56±58天(95%CI 41至71),p=0.3。
- 从首次门诊到首次化疗时间:最低三分位19±12天(95%CI 12至26),中间三分位19±14天(95%CI 11至26),最高三分位15±9.7天(95%CI 8.4至21),p=0.31。
- 手术切除时间:最低三分位99±35天(95%CI 87至111),中间三分位88±28天(95%CI 77至99),最高三分位102±64天(95%CI 86至118),p=0.24。
- 接受保肢手术比例:最低三分位84%(21/25),中间三分位83%(24/29),最高三分位81%(48/59),p=0.52。
- 5年无病生存率:最低三分位27%(95%CI 7.8%至43%),中间三分位44%(95%CI 23%至59%),最高三分位56%(95%CI 40%至67%),p=0.22;总生存率:最低三分位74%(95%CI 58%至95%),中间三分位82%(95%CI 68%至98%),最高三分位64%(95%CI 52%至78%),p=0.27;排除转移患者后的生存率:最低三分位84%(95%CI 68%至100%),中间三分位91%(95%CI 80%至100%),最高三分位68%(95%CI 55%至83%),p=0.10。
临床怎么用
- 作者认为,基于该研究结果,就医距离近、公共交通便利和区域保险政策可能有助于缩小骨肉瘤治疗中的差异。
- 作者建议未来需多中心研究进一步探讨区域差异及上述因素在骨肉瘤治疗中的作用,以帮助指导公共政策方向。
局限性
- 由于样本量小,无法控制种族和保险等潜在混杂因素。
- 作者指出未来需多中心研究进一步探讨区域差异及上述因素在骨肉瘤治疗中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The published reports examining socioeconomic factors and their relationship to osteosarcoma presentation and treatment suggest an association between lower socioeconomic status and a worse response to chemotherapy and lower survivorship. However, the driving factors behind these disparities are unclear. The Child Opportunity Index was developed by diversitydatakids.org ( https://www.diversitydatakids.org/ ) in 2014 to cumulatively quantify social determinants of health in an index specifically tailored toward a pediatric population and organized by census tract. The Childhood Opportunity Index can be used to explore the relationship between a patient's socioeconomic background and disparities in osteosarcoma presentation, treatment, and outcomes. QUESTION/PURPOSES: Are differences in a child's Childhood Opportunity Index score associated with differences in (1) time from symptom onset to first office visit for osteosarcoma, (2) timing of chemotherapy or timing and type of surgical resection, or (3) initial disease severity, development of metastatic disease, or overall survival? METHODS: A retrospective therapeutic study was conducted using data drawn from the institutional records of a large pediatric tertiary cancer center located in the Mid-Atlantic region of the United States from the years 2006 to 2022. Our main site is in an urban setting, with ample access to public transit. Patients were excluded from analysis if they were seeking a second opinion or our institution was not the main point of orthopaedic care (20% [45 of 223]). Of the remaining patients, those with incomplete electronic medical records (24% [43 of 178]), resided in an international country (5% [9 of 178]), presented after relapse (4% [8 of 178]), or lacked 2 years of follow-up at our institution (3% [5 of 178]) were excluded as well. A total of 113 pediatric patients (children younger than 18 years) met the inclusion criteria. The Child Opportunity Index is a composite index derived from three domains (education, health and environment, and social and economic) and 29 indicators within the domains that serve to capture the cumulative effect of disparities on child well-being. National Childhood Opportunity scores were collected and scored from 1 to 100. Each score represents an equal proportion of the US population of children 18 years of age or younger. A higher number indicates higher levels of socioeconomic opportunity. The overall Childhood Opportunity Index score was then broken down into three groups representative of the child's relative socioeconomic opportunity: lowest tertile for scores < 34, middle tertile for scores between 34 and 66, and highest tertile for scores > 66. Means, ranges, medians, IQRs, and percentages were used to describe the study sample. Data analysis was conducted across the three groups (lowest tertile, middle, and highest), assessing differences in time to presentation, treatment variations, disease severity, and overall survivorship. Chi-square and Fisher exact tests were applied to compare categorical variables. Mann-Whitney U tests compared continuous data. Kaplan-Meier survival analysis, stratified by Childhood Opportunity Index tertile, was performed for a 5-year period to evaluate the development of metastatic disease and overall survivorship. A log-rank test was applied to evaluate statistical significance. Due to the small sample size, we were unable to control potential confounders such as race and insurance. However, the three domains (education, health and environment, and social and economic) encapsulated by the Childhood Opportunity Index data indirectly account for disparities related to race and insurance status. RESULTS: There was no association between lower levels of socioeconomic opportunity, as expressed by the lack of difference between the Childhood Opportunity Index tertiles for the interval between symptom onset and first office visit (mean ± SD lowest tertile 77 ± 67 days [95% confidence interval (CI) 60 to 94], middle tertile 69 ± 94 days [95% CI 50 to 89], and highest tertile 56 ± 58 days [95% CI 41 to 71]; p = 0.3). Similarly, we found no association between lower levels of socioeconomic opportunity, as expressed by the lack of difference between the Childhood Opportunity Index tertiles and the time elapsed from the first office visit to the first chemotherapy session (lowest tertile 19 ± 12 days [95% CI 12 to 26], middle 19 ± 14 days [95% CI 11 to 26], and highest 15 ± 9.7 days [95% CI 8.4 to 21]; p = 0.31), the time to surgical resection (lowest tertile 99 ± 35 days [95% CI 87 to 111], middle 88 ± 28 days [95% CI 77 to 99], and highest 102 ± 64 days [95% CI 86 to 118]; p = 0.24), or the type of surgical resection (limb-sparing versus amputation: 84% [21 of 25] in lowest tertile, 83% [24 of 29] in the middle tertile, and 81% [48 of 59] in the highest tertile received limb-sparing surgery; p = 0.52). Finally, we found no differences in terms of disease-free survival at 5 years (lowest tertile 27% [95% CI 7.8% to 43%], middle 44% [95% CI 23% to 59%], and highest 56% [95% CI 40% to 67%]; p = 0.22), overall survival (lowest 74% [95% CI 58% to 95%], middle 82% [95% CI 68% to 98%], and highest 64% [95% CI 52% to 78%]; p = 0.27), or in terms of survivorship of the cohort, excluding patients who presented with metastatic disease (lowest 84% [95% CI 68% to 100%], middle 91% [95% CI 80% to 100%], and highest 68% [95% CI 55% to 83%]; p = 0.10). CONCLUSION: In our single-center retrospective study of 113 children who presented with osteosarcoma, we did not find an association between a patient's national socioeconomic opportunity and their time to presentation, chemotherapy treatment, time to and type of surgical resection, or disease-free and overall survival. Prior work has shown an association between socioeconomic background and disparities in osteosarcoma treatment. It is possible that these findings will be similar to those from other hospitals and geographic areas, but based on our findings, we believe that proximity to providers, access to public transit, and regional insurance policies may help diminish these disparities. Future multicenter studies are needed to further explore the role that regional variations and the aforementioned factors may play in osteosarcoma treatment to help inform the direction of public policy. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Kell D, Yang D, Lee J, et al. Do Patients of Different Levels of Affluence Receive Different Care for Pediatric Osteosarcomas? One Institution's Experience. Clin Orthop Relat Res. 2024. PMID: 39485923. doi:10.1097/CORR.0000000000003299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。